Korean J Fertil Steril.  2005 Dec;32(4):347-352.

Effects of Metformin and Rosiglitazone in Overweight or Obese Women with Polycystic Ovarian Syndrome

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea. kbbai@snu.ac.kr

Abstract


OBJECTIVE
The purpose of this study was to evaluate and compare the effects of metformin and rosiglitazone in overweight or obese women with polycystic ovarian syndrome.
METHODS
Twenty Six overweight or obese patients with polycystic ovarian syndrome were randomly treated with either metformin (500 mg three times daily, n=13) or rosiglitazone (4 mg once daily, n=13) for 6 months. Hormonal studies were performed before and after treatment. Insulin resistances were calculated by computerized HOMA 2 Calculator v2.2.
RESULTS
Testosterone decreased while SHBG increased after 6 months treatment in both metformin and rosiglitazone treatment groups. Fasting glucose decreased after metformin or rosiglitazone treatment. HOMA insulin resistance improved after treatment with either drug. There was no differences in hormonal changes and insulin resistance between 2 treatment groups.
CONCLUSIONS
This study shows that metformin and rosiglitazone are effective in improving insulin sensitivity and ameliorating hyperandrogenism in overweight/obese polycystic ovarian syndrome women.

Keyword

Polycystic ovarian syndrome; Metformin; Rosiglitazone; Obese; Insulin resistance
Full Text Links
  • KJFS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr